Familial Chylomicronemia Syndrome
Familial Chylomicronemia Syndrome is a rare genetic disorder that causes extremely high levels of triglycerides in the blood, leading to symptoms like abdominal pain, pancreatitis, and skin lesions.
Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study
We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you currently being treated with Waylivra (volanesorsen)?
- Have you been diagnosed with FCS (Familial Chylomicronemia Syndrome)?
- Have you taken any investigational drugs or treatments in the last 4 weeks?
- Do you have any significant medical conditions that your doctor has said could make you unsuitable for a study?
- Have you experienced any serious side effects from treatments in the past?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Isis 678354
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Karolinska University Hospital
Centre for Metabolism and Endocrinology, Department of Medicine
Huddinge, Sweden
Sponsor: Ionis Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.